Antivitamins: A Silver Lining in the Era of Antimicrobial Resistance
Nayesha Mahwish1, Laxminarayana Kurady Bairy1, Sureshkumar Srinivasamurthy1★★ Corresponding author
- 1Department of Pharmacology, Ras Al Khaimah College of Medical Sciences (RAKCOMS), RAK Medical and Health Sciences University Ras Al Khaimah (RAKMHSU), Ras Al Khaimah, United Arab Emirates.
CORRESPONDENCE
Sureshkumar Srinivasamurthy
Department of Pharmacology, Ras Al Khaimah College of Medical Sciences Campus (RAKCOMS), RAK Medical and Health Sciences University Ras Al Khaimah (RAKMHSU), Ras Al Khaimah 11172, United Arab Emirates.
Received: 06-12-2021; Revised: 24-12-2021; Accepted: 28-01-2022.
Volume 13, Issue 1 · pp. 5–13 · PUBLISHED 2022 · DOI: 10.1177/0976500X221080378
View on J Pharmacol. Pharmacother. original site ↗
ABSTRACT
Antivitamins are compounds that negate the biological effects of vitamins. They have been successfully exploited for the development of various classes of drugs. In the early 19th century, the antifolate prontosil was developed for the treatment of puerperal fever. Since then, numerous other antifolates have been used to treat a wide range of infections. Antifolates, such as methotrexate, are potent anticancer agents and antivitamin K, such as warfarin, are used as anticoagulants. Despite several years of research, most antivitamin-based drugs are limited to vitamin K and B9, and the development of antagonists for other vitamins is still in the nascent stage. In the era of antimicrobial resistance, antivitamins can be considered as a promising alternative to develop newer antimicrobials and are worth exploring further. This review discusses key antivitamins at different stages of development which have potential utility as antibiotic drug candidates. The summary of studies of antivitamins in clinical development is also narrated.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Mahwish, N., Bairy, L. K., & Srinivasamurthy, S. (2022). Antivitamins: A Silver Lining in the Era of Antimicrobial Resistance. Journal of Pharmacology and Pharmacotherapeutics, 13(1), 5–13. https://doi.org/10.1177/0976500X221080378
